$Sonnet BioTherapeutic (SONN.US)$ Sonnet BioTherapeutics Announces Safety Review Results Of SON-1010 In Combination With Trabectedin For Advanced Soft Tissue Sarcomas, Showing No Unexpected Toxicities And Clinical Benefit In 83% Of Patients, Paving The Way For Full Enrollment In Phase 1 SB101 Trial
SON-1010 is being studied as a combination therapy with trabectedin (Yondelis), the first FDA-approved treatment for two types of advanced soft tissue sarcoma after failure of standard chemothera...

$Sonnet BioTherapeutic (SONN.US)$
stocktitan.net/...

$Sonnet BioTherapeutic (SONN.US)$
Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas
Wednesday, 26th March at 9:05 am
SON-1010 is being studied as a combination therapy with trabectedin (Yondelis®), the first FDA-approved treatment for two types of advanced soft tissue sarcoma after failure of standard chemotherapy, due to the potential for immune mechanism synergies and enhancement of progression-free survival (P...

$Sonnet BioTherapeutic (SONN.US)$
Major Patent Win: Sonnet's Revolutionary IL-18 Cancer Treatment Shows Superior Binding Properties

$Sonnet BioTherapeutic (SONN.US)$
Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors
Wednesday, 26th February at 9:00 am
Poster presented at the 2025 AACR:IO Conference
Company's novel platform that delivers either mono- or bifunctional immunomodulators linked to a Fully-Human, Albumin Binding scFv domain (FHAB®) provides enhanced targeting to the tumor microenvironment...

$Sonnet BioTherapeutic (SONN.US)$ Reuters· 3 mins ago
Sonnet Biotherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform Is Available for Drug Discovery Partnerships With Potential for Producing Multiple Pipeline Drug Candidates

$Sonnet BioTherapeutic (SONN.US)$
Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology
Tuesday, 28th January at 9:05 am
European Patent Office (EPO) grants EU Patent No. EP3583125 B1 covering the Company's Fully Human Albumin Binding (FHAB®) domain fusion proteins
In addition to the U.S. and EU, Sonnet's global IP coverage
now extends to China, Japan, Russia and New Zealand
Management releases "What This Mea...

$Sonnet BioTherapeutic (SONN.US)$ Sonnet BioTherapeutics Has Been Granted European Patent Number EP3583125 Titled "ALBUMIN BINDING DOMAIN FUSION PROTEINS (FOR THE TREATMENT OF CANCER)".
Benzinga· just

$Sonnet BioTherapeutic (SONN.US)$
Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas
Tuesday, 21st January at 9:05 am
SON-1010, after receipt of data suggesting clinical benefit when administered as a monotherapy in patients with advanced solid tumors, enters combination evaluation with trabectedin (Yondelis®) with the potential to improve trabectedin's therapeutic window in soft-tissue sarcoma patients
Combined mechan...